Literature DB >> 36267437

Guillain-Barré syndrome associated with vaccines in Veracruz, Mexico.

Luis Del Carpio-Orantes1, Ishar Solís-Sánchez1, Yuri Omar Piquet-Uscanga1.   

Abstract

Entities:  

Year:  2022        PMID: 36267437      PMCID: PMC9578311          DOI: 10.4103/bc.bc_25_22

Source DB:  PubMed          Journal:  Brain Circ        ISSN: 2394-8108


× No keyword cloud information.
  9 in total

Review 1.  Vaccine-preventable diseases, vaccines and Guillain-Barre' syndrome.

Authors:  Nicola Principi; Susanna Esposito
Journal:  Vaccine       Date:  2018-06-04       Impact factor: 3.641

2.  Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.

Authors:  Kayla E Hanson; Kristin Goddard; Ned Lewis; Bruce Fireman; Tanya R Myers; Nandini Bakshi; Eric Weintraub; James G Donahue; Jennifer C Nelson; Stan Xu; Jason M Glanz; Joshua T B Williams; Jonathan D Alpern; Nicola P Klein
Journal:  JAMA Netw Open       Date:  2022-04-01

3.  A variant of Guillain-Barre syndrome after SARS-CoV-2 vaccination: AMSAN.

Authors:  Nurhan Kaya Tutar; Tuğba Eyigürbüz; Zerrin Yildirim; Nilufer Kale
Journal:  Ideggyogy Sz       Date:  2021-07-30       Impact factor: 0.427

Review 4.  Vaccines and Guillain-Barré syndrome.

Authors:  Penina Haber; James Sejvar; Yann Mikaeloff; Frank DeStefano
Journal:  Drug Saf       Date:  2009       Impact factor: 5.228

5.  Post-adenoviral-based vaccines Guillain-Barre Syndrome: A proposed mechanism.

Authors:  Kamran Kadkhoda
Journal:  Med Hypotheses       Date:  2022-02-12       Impact factor: 1.538

6.  Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis.

Authors:  Fengge Wang; Donglan Wang; Yingjie Wang; Cancan Li; Yulu Zheng; Zheng Guo; Pengcheng Liu; Yichun Zhang; Wei Wang; Youxin Wang; Haifeng Hou
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 7.561

7.  Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine.

Authors:  Miguel García-Grimshaw; Anaclara Michel-Chávez; Juan Mauricio Vera-Zertuche; Javier Andrés Galnares-Olalde; Laura E Hernández-Vanegas; Melissa Figueroa-Cucurachi; Orlando Paredes-Ceballos; Gustavo Reyes-Terán; Guillermo Carbajal-Sandoval; Santa Elizabeth Ceballos-Liceaga; Antonio Arauz; Sergio Iván Valdés-Ferrer
Journal:  Clin Immunol       Date:  2021-08-03       Impact factor: 3.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.